Redmond, Wash.-based EchoNous announces that the U.S. FDA has cleared Lexsa, the company’s new 128-channel linear probe, for use in all U.S. medical practices. Lexsa was designed specifically for the Kosmos platform, the first “hybrid” point-of-care ultrasound (POCUS) tool—defined as an ultra-portable device capable of producing diagnostic-quality images like cart-based units.
Lexsa connects to the Kosmos Bridge platform as well as Android S6 tablets—with S7 available soon—to produce high-level image quality for nerve, lung, vascular, and musculoskeletal ultrasound at the bedside. The Kosmos platform now offers three transducer probes, enabling POCUS imaging of nearly the entire anatomy wherever needed.
With high-quality imaging capabilities in extremities, Lexsa is positioned to become a critical ultrasound tool for central line placement, nerve blocks, and guiding injections into joints, company officials say. The POCUS device also has the potential to improve safety and ease-of-placement while reducing the risk of infection, they add.
“The FDA clearance of our Lexsa probe is not only a significant milestone for EchoNous, but a major advancement in ultraportable point-of-care ultrasound technology,” says Kevin Goodwin, CEO of EchoNous. “Lexsa will broaden the application of our Kosmos imaging platform beyond its current focus on cardiology, abdominal, and pulmonology; enabling entry into other departments that require linear capabilities for diagnosis or interventional use.”
He continues, “Already favored for its built-in AI guidance and mapping around heart and lung structures, Kosmos will now gain traction as the ideal POCUS tool across multiple healthcare specialties.”
